BloodPAC published standardized analytical-validation protocols for tumor‑informed circulating tumor DNA (ctDNA) assays, setting a common blueprint for how companies should demonstrate limit of detection, accuracy, precision and stability for minimal residual disease (MRD) tests. The consortium’s work, published in JCO Precision Oncology, was authored by an MRD working group that includes experts from industry, academia and regulators. At JPM, Veracyte outlined commercial plans for TrueMRD and the company’s new whole‑transcriptome v2 platform, saying the MRD test will debut in H1 and initially target muscle‑invasive bladder cancer (MIBC) surveillance. Veracyte executives signaled parallel launches for sequencing‑based Prosigna offerings and a pipeline of MRD indications across breast, lung, kidney and colorectal cancer. Taken together, the BloodPAC protocols and Veracyte’s product timetable narrow analytical and commercial uncertainty for MRD tests, clarifying validation expectations and the practical path companies plan to follow to bring sequencing‑based MRD assays into clinical practice.